\
&
Contact us
\
&
Contact us
This was 3 weeks ago
LocationOnline
ProgrammesThis AI Pact webinar will focus on AI Innovation for SMEs and Startups: Sandboxes, real-world testing, AI Act Service Desk and European Digital Innovation Hubs (EDIHs).
It will explore how the European Union is fostering AI innovation while ensuring compliance with the AI Act and reducing administrative and financial barriers for SMEs.
This webinar addresses mainly SMEs, startups, AI developers, policymakers, and stakeholders interested in understanding how the EU is supporting AI innovation while ensuring compliance with regulatory frameworks. It will present practical tools and resources available to support testing AI and implementing the AI Act correctly.
More information on the event, which will be live streamed, is available on the event website.
Background:
The European Commission's AI Office hosts events within the AI Pact to engage the AI community, promote knowledge sharing, and best practices to foster trustworthy AI.The AI Pact encourages organisations to prepare for the implementation of the AI Act.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
